Please Wait
Applying Filters...
Menu
Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 2Byooviz

02 20Lucentis

PharmaCompass

01

Brand Name : Lucentis

Ranibizumab

arrow
Pharmtech & Ingredients
Not Confirmed

Brand Name : Lucentis

arrow
Pharmtech & Ingredients
Not Confirmed

Ranibizumab

Main Therapeutic Indication : Ophthalmology

Currency : USD

2019 Revenue in Millions : 1,881

2018 Revenue in Millions : 1,709

Growth (%) : 10

blank

02

Brand Name : Lucentis

Ranibizumab

arrow
Pharmtech & Ingredients
Not Confirmed

Brand Name : Lucentis

arrow
Pharmtech & Ingredients
Not Confirmed

Ranibizumab

Main Therapeutic Indication : Ophthalmology

Currency : USD

2020 Revenue in Millions : 1,609

2019 Revenue in Millions : 2,034

Growth (%) : -21

blank

03

Brand Name : Lucentis

Ranibizumab

arrow
Pharmtech & Ingredients
Not Confirmed

Brand Name : Lucentis

arrow
Pharmtech & Ingredients
Not Confirmed

Ranibizumab

Main Therapeutic Indication : Ophthalmology

Currency : USD

2020 Revenue in Millions : 1,933

2019 Revenue in Millions : 2,086

Growth (%) : -7

blank

04

Brand Name : Lucentis

Ranibizumab

arrow
Pharmtech & Ingredients
Not Confirmed

Brand Name : Lucentis

arrow
Pharmtech & Ingredients
Not Confirmed

Ranibizumab

Main Therapeutic Indication : Ophthalmology

Currency : USD

2021 Revenue in Millions : 1,456

2020 Revenue in Millions : 1,531

Growth (%) : -6

blank

05

Brand Name : Lucentis

Ranibizumab

arrow
Pharmtech & Ingredients
Not Confirmed

Brand Name : Lucentis

arrow
Pharmtech & Ingredients
Not Confirmed

Ranibizumab

Main Therapeutic Indication : Ophthalmology

Currency : USD

2021 Revenue in Millions : 2,160

2020 Revenue in Millions : 1,933

Growth (%) : 12

blank

06

Brand Name : Lucentis

Ranibizumab

arrow
Pharmtech & Ingredients
Not Confirmed

Brand Name : Lucentis

arrow
Pharmtech & Ingredients
Not Confirmed

Ranibizumab

Main Therapeutic Indication : Ophthalmology

Currency : USD

2022 Revenue in Millions : 1,874

2021 Revenue in Millions : 2,160

Growth (%) : -13

blank

07

Brand Name : Byooviz

Ranibizumab-nuna

arrow
Pharmtech & Ingredients
Not Confirmed

Brand Name : Byooviz

arrow
Pharmtech & Ingredients
Not Confirmed

Ranibizumab-nuna

Main Therapeutic Indication : Ophthalmology

Currency : USD

2022 Revenue in Millions : 4

2021 Revenue in Millions : 0

Growth (%) : New Launch in 2022

blank

08

Brand Name : Byooviz

Ranibizumab-nuna

arrow
Pharmtech & Ingredients
Not Confirmed

Brand Name : Byooviz

arrow
Pharmtech & Ingredients
Not Confirmed

Ranibizumab-nuna

Main Therapeutic Indication : Ophthalmology

Currency : USD

2023 Revenue in Millions : 32

2022 Revenue in Millions : 4

Growth (%) : 637

blank

09

Brand Name : Lucentis

Ranibizumab

arrow
Pharmtech & Ingredients
Not Confirmed

Brand Name : Lucentis

arrow
Pharmtech & Ingredients
Not Confirmed

Ranibizumab

Main Therapeutic Indication : Ophthalmology

Currency : USD

2022 Revenue in Millions : 1,106

2021 Revenue in Millions : 1,456

Growth (%) : -24

blank

10

Brand Name : Lucentis

Ranibizumab

arrow
Pharmtech & Ingredients
Not Confirmed

Brand Name : Lucentis

arrow
Pharmtech & Ingredients
Not Confirmed

Ranibizumab

Main Therapeutic Indication : Ophthalmology

Currency : USD

2023 Revenue in Millions : 1,475

2022 Revenue in Millions : 1,874

Growth (%) : -21

blank